February 2018 Vol 11, No 1
Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Age Adults in the United States
J. Douglas Thornton, PharmD, PhD, Nilanjana Dwibedi, PhD, Virginia Scott, PhD, Charles D. Ponte, PharmD, Douglas Ziedonis, MD, Nethra Sambamoorthi, PhD, Usha Sambamoorthi, PhD
Chronic noncancer pain is prevalent among US adults, costs approximately $600 billion annually, and can be especially burdensome for working-age adults because of lost productivity and the negative impact of this condition on a patient’s quality of life.
Addiction Prediction: Preventing Iatrogenic Opioid Dependence
Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines
Gabriela Dieguez, FSA, MAAA, Christine Ferro, Maushumi Mavinkurve, MPH, Yuri Sanchez Gonzalez, PhD, Bruce Pyenson, FSA, MAAA
Chronic hepatitis C virus (HCV) infection kills more people than any other infectious disease in the United States, and, as of 2013, mortality associated with this disease has been rising.
Importance of Health Outcomes Research for the Treatment of Hepatitis C Infection
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Approximately 30,000 new cases of multiple myeloma are diagnosed annually in the United States, and 12,650 deaths annually are attributed to multiple myeloma.
Improved Clinical Outcomes with Newer Multiple Myeloma Therapies Associated with Increased Resource Utilization and Financial Burden
When this view into 2018 was developed, Senate failures to repeal, replace, or change the Affordable Care Act (ACA) had occurred, and left the market unchanged from a legislative perspective. Regardless, relentless market change before and after the implementation of the ACA has left ACA exchanges in financial trouble, providers facing decreased reimbursement, and consumers with limited access to plans by metropolitan statistical area across the country.
Results 1 - 5 of 5